

## Press Release

**Revenue up 14% to Rs. 1475 crores in Q2 FY23.**

**Vadodara, November 11<sup>th</sup>, 2022**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter and half year ended 30<sup>th</sup> September, 2022.

### Financial Highlights

- Net Sales for the quarter up 14% to Rs. 1475 crores.
- Net Profit for the quarter at Rs. 133 crores.
- Net sales for H-1 FY23 at Rs. 2737 crores.
- Net profit for H-1 FY23 at Rs. 67 crores.

**Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited** said “It was a satisfactory quarter led by growth in all the verticals of the company, in particular the API business outperformed with a 23% growth during the quarter”

### Operational Highlights

#### India Formulations Business

- India Formulations Business grew at 11% (Excluding one time non recurring sales of Amphotericin – B) to Rs. 549 crores in the quarter.
- India Growth for the quarter is on back of exceptionally high market growth in Q2 FY 21-22. Alembic clocked a large out-performance vs market.
- Specialty segment grew faster than the market.

#### International Business

- US Generics grew 20% to Rs. 418 crores in the quarter.
- Ex-US International Formulations grew 9% to Rs. 215 Crores in the quarter.
- 3 ANDA approvals received during the quarter; 170 Cumulative ANDA approvals.
- 5 ANDA filings during the quarter; Cumulative ANDA filings at 242.

#### API Business

- API business grew 23% at Rs. 294 crores in the quarter.
- 126 cumulative DMF Filings.



## **ALEMBIC PHARMACEUTICALS LIMITED**

